Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries

Moran, Andrew E., Farrell, Margaret, Cazabon, Danielle, Sahoo, Swagata Kumar, Mugrditchian, Doris, Pidugu, Anirudh, Chivardi, Carlos, Walbaum, Magdalena ORCID: 0000-0002-2179-9224, Alemayehu, Senait, Isaranuwatchai, Wanrudee, Ankurawaranon, Chaisiri, Choudhury, Sohel R., Pickersgill, Sarah J., Watkins, David A., Husain, Muhammad Jami, Rao, Krishna D., Matsushita, Kunihiro, Marklund, Matti, Hutchinson, Brian, Nugent, Rachel, Kostova, Deliana and Garg, Renu (2022) Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries. Revista Panamericana de Salud Publica/Pan American Journal of Public Health, 46. ISSN 1020-4989

Text (Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (328kB)

• Author

Abstract

Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in lowand middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.

Item Type:	Article
Additional Information:	© 2022 Pan American Health Organization.
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	02 Dec 2022 16:27
Last Modified:	12 Dec 2024 03:27
URI:	http://eprints.lse.ac.uk/id/eprint/117509

Actions (login required)

View Item